Research

Energy balance

The role of GLP-1 receptor agonists in obesity-related HFpEF remains unclear.

Further research is needed to clarify the role of GLP-1 receptor agonists in managing obesity-related HFpEF.

StrongQualifiesmedium confidence
Despite the well-documented benefits of GLP-1 receptor agonists in subjects with diabetes, obesity, or both, their role in obesity-related HFpEF remains unclear.
Paschalis Karakasis et al. · Biomedicines · 2024

Why this rating

The claim is based on a synthesis of available clinical evidence.

Source

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?

Paschalis Karakasis et al. · Biomedicines · 2024

DOI 10.3390/biomedicines12092112

reviewCited 29×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →